Maui Derm

Other Key Congresses

Maui Derm
Other Congresses

2026
2025

January 25-29, 2026, Grand Wailea, Maui, Hawaii

Remibrutinib improves urticaria symptoms, quality of life, and sleep: An analysis from REMIX-1/-2 studies

Mark Lebwohl, Vipul Jain, Michihiro Hide, Hao Cheng, Petra Staubach-Renz, Sibylle Haemmerle, Christine Elke Ortmann, El-Djouher Martzloff, Karine Lheritier, Hugh Windom

Poster

Early and sustained efficacy of remibrutinib in adult patients with CSU: Pooled analysis of REMIX-1/-2 studies

Shaila Gogate, Michael Palumbo, Ana Maria Giménez-Arnau, Shiqin Tao, Michihiro Hide, Karine Lheritier, Paula Machado, Knut Brockow

Poster

Concomitant use of antiplatelet agents with remibrutinib in the Phase 3 REMIX-1/-2 studies

Lindsey Finklea, Michael Palumbo, Alis Burciu, Sibylle Haemmerle

Poster

January 20-24, 2025, Maui, Hawaii

Pooled REMIX-1/-2 phase 3 data: Early and sustained symptom improvement with remibrutinib in chronic spontaneous urticaria

S. Saini, G. Mosnaim, A.G-Arnau, L. Li, El-D. Martzloff, A. Burciu, K. Lheritier, M. Metz

ePoster

2026
2025

EAC (Eastern Allergy Conference)

May 28 -31, 2026 | The Breakers, Palm Beach, Florida

Early Real-World Effectiveness of Remibrutinib in Patients With Chronic Spontaneous Urticaria (CSU) in the United States (US): Week 1 Data From the RELIEF Study

David M. Lang, Dhaval Patil, Merin Kuruvilla, Helen Chen, Sophie Jacobovitz, Naiem Issa

Abstract Poster Presentation

Remibrutinib in Real-World Clinical Practice: Addressing Challenges in Chronic Spontaneous Urticaria (CSU) — The REASSERT Study

Sarbjit Saini, Martin Metz, Zuotao Zhao, Koremasa Hayama, April Armstrong, Tara Raftery, Nadine Chapman-Rothe, Dhaval Patil, Ana M. Giménez-Arnau

Abstract Poster Presentation

Remibrutinib Demonstrated Superior Efficacy vs Placebo With a Favorable Safety Profile in Patients With Symptomatic Dermographism in the Phase 3 REMIND Study

Giselle Mosnaim, Ana Maria Giménez-Arnau, Lindsey Finklea, Koremasa Hayama, Michihiro Hide, Johannes S Kern, Moisés Labrador-Horrillo, Philip H Li, Heike Rockmann, Sarbjit Saini, Sebastian Volc, Jinhua Xu, Bin Yang, Alis Burciu, Li Chen, Clarice Field, Sibylle Haemmerle, Karine Lheritier, Miriam Porter, Martin Metz

Abstract Oral Presentation

Other Congress

March 27-31, 2026, Denver, Colorado, USA

A pooled analysis of the hemostatic safety profile of remibrutinib over 24 weeks in patients with chronic spontaneous urticaria from the REMIX-1 and REMIX-2 phase 3 studies

Mark Lebwohl, Sarbjit Saini, Michihiro Hide, Frederic Berard, Linfeng Li, Elodie Incera, Hichem Zouater, Karine Lheritier, Artem Zharkov, Knut Brockow

ePoster With Oral Presentation

Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily itch severity scores and hives severity scores from phase 3 REMIX-1/-2 studies

Giselle Mosnaim, Petra Staubach, Bin Yang, Atsushi Fukunaga, El-Djouher Martzloff, Nadine Chapman-Rothe, Tao Ding, Gordon Sussman, Ana Maria Giménez-Arnau

ePoster With Oral Presentation

Specific autoantibodies may contribute to chronic spontaneous urticaria in a BTK-dependent manner

Martin Metz, Sarbjit Saini, Michihiro Hide, Theodoulos Rodosthenous, Alexandre Avrameas, Annika Loredana Kilian, Petra Budde, Hans-Dieter Zucht, Ulf Gehrmann, Nadine Chapman-Rothe, Sibylle Haemmerle

ePoster

Urticaria Voices: Treatment patterns and disease control in patients with self-reported chronic inducible urticaria

Giselle Mosnaim, Sabine Altrichter, Karsten Weller, Tonya A. Winders, Jessica McCarthy, Pallavi Saraswat, Nadine Chapman-Rothe, Tara Raftery, Jonathan A. Bernstein

ePoster

Out-of-pocket expenses in patients with chronic inducible urticaria (CIndU): Results from Urticaria Voices study

Tonya A. Winders, Jonathan A. Bernstein, Giselle Mosnaim, Tara Raftery, Nadine Chapman-Rothe, Jessica McCarthy, Panagiotis Orfanos, Ravneet Kaur Kohli, Dhaval Patil, Karsten Weller, Sabine Altrichter

ePoster

Design of the REASSERT Study: A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU)

April W. Armstrong, Sarbjit Saini, Martin Metz, Zuotao Zhao, Tara Raftery, Nadine Chapman-Rothe, Iftekhar Khan, Dhaval Patil, Ana M. Giménez-Arnau

ePoster

Patients with chronic spontaneous urticaria (CSU) in the United States (US): Health care and economic burden associated with corticosteroid use

Gil Yosipovitch, Dhaval Patil, Jonathan Rodrigues, Merin Kuruvilla, Jason Doran, Irina Pivneva, Frédéric Kinkead, Panagiotis Orfanos, Tara Raftery, Marc A. Riedl

ePoster

Out-of-pocket expenses in patients with chronic spontaneous urticaria: Results from Urticaria Voices

T.A. Winders, J.A. Bernstein, T. Raftery, N.C-Rothe, J. McCarthy, P. Saraswat, P. Orfanos, R.K. Kohli, D. Patil, K. Weller

ePoster

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria (CSU) up to week 52 in the REMIX-1/-2 studies

R. Snyder, Y. Bin, D. Merritt, S.F. Thomsen, A. Fukunaga, C. Field, S. Haemmerle, C-Ya. Chu, N. Seko, M. Metz

ePoster

Improvements in itch and hive symptoms with remibrutinib as early as week 1 in patients with chronic spontaneous urticaria (CSU) in REMIX-1/-2

M. Scarupa, S. Dinehart, X. Jiang, L. Finklea, J. Reed, Y.M. Ye, C. Field, S. Haemmerle, P. Wang, G. Sussman

ePoster

Effects of remibrutinib treatment on ambulatory blood pressure in adult patients with chronic spontaneous urticaria (CSU)

M. Palumbo, G. Mosnaim, U. Lippert, S. Haemmerle, M.F. Eigenmann, K. Lheritier, A. Zharkov, P. Machado, I. Rodriguez, M.G. Lebwohl

ePoster

Cookie Settings